Matthew Might, director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham, is drawing on his own experience as the parent of a child with a rare disease to create a framework for others in his situation. Might is a proponent of testing already approved drugs to see whether they work against rare diseases, though he acknowledges identifying treatments for some complex diseases is not so simple and says "there's a gap between diagnostics and therapeutics."
Road map for treating rare diseases includes repurposing drugs
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.